Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.81 |
| ▸ | MAOB | P27338 | 16/20 | 0.81 |
| ▸ | DRD2 | P14416 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16559664 | 0.89 | MAOA (1.00) | MAOAMAOBDRD2 | |
| SCHEMBL25570556 | 0.89 | MAOA (0.83) | MAOAMAOBDRD2 | |
| SCHEMBL10672507 | 0.87 | DRD2 (0.67) | MAOAMAOBDRD2 | |
| SCHEMBL10568393 | 0.85 | MAOA (0.77) | MAOAMAOBDRD2 | |
| SCHEMBL2842062 | 0.85 | MAOB (0.80) | MAOAMAOBDRD2 | |
| SCHEMBL10571777 | 0.84 | MAOA (0.74) | MAOAMAOBDRD2 | |
| SCHEMBL10571208 | 0.84 | MAOA (0.79) | MAOAMAOBDRD2 | |
| SCHEMBL10573572 | 0.84 | MAOA (0.79) | MAOAMAOBDRD2 | |
| SCHEMBL10665990 | 0.84 | DRD2 (1.00) | MAOAMAOBDRD2 | |
| SCHEMBL10576593 | 0.83 | DRD2 (0.98) | MAOAMAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279696-B2 | Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one | MSN LABORATORIES PRIVATE LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| WO-2018087775-A1 | PROCESSES FOR THE PREPARATION OF 7-{4-[4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL]BUTOXY}QUINOLIN-2(1H)-ONE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-17 | — | — | WO | disclosed |
| US-7872132-B2 | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| US-7872132-B2 | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| US-20090203907-A1 | Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203907-A1 | Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| WO-2006038220-A1 | NOVEL INTERMEDIATES USEFUL FOR THE PREPARATION OF ARIPIPRAZOLE AND METHODS FOR THE PREPARATION OF THE NOVEL INTERMEDIATES AND ARIPIPRAZOLE | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203907-A1 | Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | CYP2J2, CYP2B6, CYP2C19 | MAOA 430/4885MAOB 328/4885DRD2 106/4885 |
| US-11279696-B2 | Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one | CYP1B1, CYP4B1, CYP1A1 | MAOA 1571/4885MAOB 1434/4885DRD2 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.